期刊文献+

欧洲药学监护网络基金会分类系统在老年2型糖尿病高血压病人药物相关问题中的应用 被引量:11

Application of pharmaceutical care network Europe classification system to drug-related problems in type2 diabetes elderly patients with hypertension
下载PDF
导出
摘要 目的将欧洲药学监护网络基金会(PCNE)分类系统用于临床病例中,探讨PCNEV8.02分类系统在老年2型糖尿病高血压病人相关问题中的应用。方法选取2019年1—12月南京医科大学附属老年医院2型糖尿病高血压老年病人176例,采用PCNE对其用药相关性问题进行分析,并对两个具体案例药物相关问题(DRPs)的类型、原因、干预、干预接受程度及DRPs状态进行系统分析。结果参与者男性114例(64.8%)。年龄为(72.8±9.41)岁。用药种数(7.77±2.55)种。最常使用的抗糖尿病药物是二甲双胍(111例,占63.07%)和阿卡波糖(87例,占49.43%)。钙离子拮抗剂是最常用的降压药,有131例(74.43%)服用。97例(55.11%)使用了抗血小板药物。112例(63.64%)服用调血脂药物。总共确定了385个药物相关问题。与药物相关的问题的数量为(2.19±0.87)个。最常见的药物相关问题是药物的相互作用(39.22%),存在适应证未给相应的药物治疗(26.49%)和选药不适宜(7.79%)。结论临床药师通过PCNE分类系统可系统地、规范化地对病人实施药学监护,能及时发现和解决DRPs,确保临床用药的安全、有效、合理。 Objective To apply the pharmaceutical care network Europe association classification system(PCNE V8.02)to clinical cases,and to explore its application in the elderly patients with type 2 diabetes and hypertension.Methods One hundred and seventy-six elderly patients with type 2 diabetes and hypertension in the Affiliated Geriatrics Hospital of Nanjing Medical University from Janu⁃ary to December 2019 were selected to analyze the drug-related problems(DRPs)by PCNE.The types,causes,interventions,interven⁃tion acceptance and DRPs status of two specific cases were analyzed systematically.Results There were 114 male participants(64.8%).The age was(72.8±9.41)years old.The number of drug species was(7.77±2.55).The most commonly prescribed antidiabetic medications were metformin(111 cases,63.07%)and acarbose(87 cases,49.43%).Calcium antagonist was the most commonly pre⁃scribed antihypertensive drugs,131(74.43%)participants used them.Antiplatelet drugs were prescribed to 97(55.11%)patients.Lip⁃id-Lowing Agents were prescribed to 112(63.64%)patients.A total of 385 drug related problems were identified.The mean number of drug related problems was(2.19±0.87).The most frequent types of DRP were potential drug-drug interaction(39.22%),no correspond⁃ing drug treatment for indications(26.49%)and inappropriate drug selection(7.79%).Conclusion Through PCNE classification sys⁃tem,clinical pharmacists can carry out pharmaceutical care for patients systematically and normatively,discover and solve DRPs in time,and ensure the safety,effectiveness and rationality of clinical medication.
作者 谢龙 谈震 曲国红 智俊娜 王怡 XIE Long;TAN Zhen;QU Guohong;ZHI Junna;WANG Yi(Department of Pharmacy,Geriatric Hospital of Nanjing Medical University,Jiangsu Province Official Hospital,Jiangsu,Nanjing 210024,China)
出处 《安徽医药》 CAS 2022年第5期1052-1057,共6页 Anhui Medical and Pharmaceutical Journal
基金 江苏省药学会药学服务专项科研资助项目(A201812) 南京药学会—常州四药医院药学科研基金资助课题(2018YX022)。
关键词 药学服务 糖尿病 2型 高血压 欧洲医药保健网 药物相关问题 Pharmaceuticalservices Diabetesmellitus,type2 Hypertension PCNEclassificationsystem Drug-relatedproblems
  • 相关文献

参考文献7

二级参考文献66

  • 1高立.祛痰宁对呼吸道疾病386例的疗效[J].新药与临床,1989,8(6):343-346. 被引量:2
  • 2胡大一,孙艺红.正确认识阿司匹林“抵抗”[J].中华心血管病杂志,2006,34(12):1057-1058. 被引量:10
  • 3温绍君,刘洁琳,刘雅,王佐广.降血压药物的潜在不良反应及其预防[J].药物不良反应杂志,2007,9(3):172-176. 被引量:12
  • 4Matzke H. Experienceswith Gelomyrtol in the treatment of bronchitis[J].MunchMedWochenschr, 1961, 29 (103) : 1881- 1882.
  • 5Kurz JF. Secretolysis through gelomyrtol [J].ZAllgemeinmed, 1970, 46 (32): 1623-1627.
  • 6Matthys H, de Mey C, Carls C, et al, Efficacy and tolerability ofmyrtol standardized in acute bronchitis [J]. Arzneimittelforschung, 2000, 50 (8):700-711.
  • 7UlmerWT, SchottD. Chronic obstructive bronchitis. Effect of Gelomyrtol forte in a p lacebocontrolled double2blind study [J].Fortschr Med, 1991, 109 (27): 547-550.
  • 8Sengespeik HC, Zimmermann T, Peike C, et al. Myrtol standardized in the treatment of acute and chronic respiratory infections in children [J]. Arzneimittelforschung, 1998, 48 (10) : 990-994.
  • 9Meister R, Wittig T, BeuscherN, et al. Efficacy and tolerability ofmyrtol standardized in longterm treatment of chronic bronchitis. A double blind, placebocontrolled study. Study Group Investigators[J]. Arzneimittelforschung, 1999, 49 ( 4 ): 351-358.
  • 10Beuscher N, Kietzmann M, Bien E, et al. Interference of Myrtol Standardized with Inflammatory and Allergic Mediators [J].Arzneimittelforsehung, 1998, 48 (10): 985-989.

共引文献5240

同被引文献135

引证文献11

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部